CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
CorMedix Therapeutics (Nasdaq: CRMD) reported Q2 2026 consolidated revenue of $101.9M, including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M and adjusted EBITDA $58.7M. The company maintained FY2026 revenue guidance at $325M-$345M and raised adjusted EBITDA to $125M-$140M, with a REZZAYO sNDA FDA submission expected in Q3 2026.
How this was made
The 30-second read
Why it matters
The combination of Q2 results, a raised FY adjusted EBITDA range, and a defined near-term regulatory submission expectation can re-rate near-term fundamentals, while the DefenCath supply agreement supports revenue visibility.
Market read
This is a company-specific earnings and business update with multiple forward-looking milestones (FDA submission timing, H1 2027 action expectation, and DefenCath ordering/pilot).
What to watch
The article flags the post-TDAPA reimbursement environment for DefenCath; traders may need to monitor whether utilization and pricing hold as new ordering ramps from the LDO pilot.
Background
CorMedix is a biopharma commercializing DefenCath and developing REZZAYO, with recent context of post-TDAPA reimbursement pressure.
Ticker impact
CorMedix reported Q2 2026 revenue of $101.9M and raised FY 2026 adjusted EBITDA guidance to $125 to $140M.
Likely positive bias into the earnings call, with follow-through tied to FDA acceptance timing and DefenCath ordering momentum.
The article discloses multiple decision-relevant updates: Q2 financial datapoints, raised FY adjusted EBITDA range, expected third-quarter sNDA submission with H1 2027 action if accepted, and a multi-year DefenCath supply agreement with commenced ordering and a pilot.
Market effects
Adds incremental signal on demand/utilization for dialysis-related therapeutics and on FDA submission cadence for antifungal prophylaxis expansion.
Primarily US small-cap biotech sentiment, with limited direct regional spillover.
Mundipharma collaboration and FDA timeline can influence cross-border partner expectations, but impact is company-specific.
Counterpoint
Raised adjusted EBITDA guidance may be partially driven by acquisition-related scale and non-GAAP adjustments, so cash flow and post-reimbursement dynamics could still disappoint.
Key entities
- public_companyCorMedix Therapeutics
Nasdaq-listed biopharmaceutical company reporting Q2 2026 results and updating FY 2026 guidance.
- productDefenCath
Taurolidine and heparin product; Q2 net revenue $66.1M and new multi-year supply agreement with a large dialysis operator.
- productREZZAYO
Antifungal therapy; company anticipates third-quarter sNDA submission for expanded prophylaxis indication.
- partnerMundipharma
Global development partner collaborating on the REZZAYO sNDA submission.
